NCT02195427 is a NA clinical trial of TEOSYAL® RHA Global Action in Nasolabial Folds, Wrinkles, sponsored by Teoxane SA.

Who is sponsoring NCT02195427?

NCT02195427 is sponsored by Teoxane SA.

What drugs are being tested in NCT02195427?

Interventions in NCT02195427: TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines.

What condition does NCT02195427 study?

NCT02195427 studies Nasolabial Folds, Wrinkles.

Is NCT02195427 still recruiting?

NCT02195427 is currently completed. Last updated 26 March 2018.

Are results published for NCT02195427?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-03-26 · How we verify

NCT02195427

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Controlled, Randomized, Double-Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA Global Action and TEOSYAL® RHA Deep Lines Versus Juvéderm® Ultra XC in the Treatment of Moderate to Severe Nasolabial Folds

Completed NA Results posted Last updated 26 March 2018

What this trial tests

NA trial testing TEOSYAL® RHA Global Action in Nasolabial Folds, Wrinkles in 148 participants. Completed in 1 March 2016.

Timeline

1 June 2014

Primary endpoint
1 March 2015

1 March 2016

Quick facts

Lead sponsor	Teoxane SA
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	148
Start date	1 June 2014
Primary completion	1 March 2015
Estimated completion	1 March 2016
Sites	5 locations across United States

Drugs / interventions tested

TEOSYAL® RHA Global Action
TEOSYAL® RHA Deep Lines

Conditions studied

Nasolabial Folds, Wrinkles — all drugs for Nasolabial Folds, Wrinkles →

Sponsor

Teoxane SA

Who can join

22 and older, any sex, with Nasolabial Folds, Wrinkles. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Non-inferiority of the Delta of TEOSYAL® RHA GA and TEOSYAL® RHA DL Versus Juvéderm® Ultra XC for the Correction of Moderate to Severe NLFs Based on the Wrinkle Severity Rating Scale (WSRS) Score Assessed by the Blinded Live Evaluator (BLE).
Time frame: Baseline and 24 weeks after last treatment
TEOSYAL® RHA GA = TEOSYAL® RHA Global Action TEOSYAL® RHA DL = TEOSYAL® RHA Deep Lines WSRS (Wrinkle Severity Rating Scale) is a validated 5-point scale assessing wrinkle severity with 1 being 'absent' and 5 being 'extreme' BLE = Blinded Live Evaluator

Sponsor's own description

The purpose of this study is 1) to compare the effectiveness and safety of TEOSYAL® RHA Global Action versus Juvéderm® Ultra XC, and 2) to compare the effectiveness and safety of TEOSYAL® RHA Deep Lines versus Juvéderm® Ultra XC, in the treatment of moderate to severe nasolabial folds.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effectiveness and Safety of Resilient Hyaluronic Acid (RHA) Dermal Fillers for the Correction of Moderate-to-Severe Nasolabial Folds in People of Color: Post Hoc Subgroup Analyses of US Pivotal Clinical Data.
Taylor S, Weinkle S, Kaufman-Janette J, Gallagher CJ, et al · · 2024 · cited 1× · PMID 37556827 · DOI 10.1093/asj/sjad251

Verify or expand the search:

Other recruiting trials for Nasolabial Folds, Wrinkles

Currently open trials in the same condition.

NCT07467239 — A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds · NA · recruiting

Other Teoxane SA trials

Trials by the same sponsor.

NCT06749587 — TEOSYAL RHA® 1 for the Correction of Moderate to Severe Tissue Volume Deficiency in the Infraorbital Region in Chinese A · NA · recruiting
NCT07145905 — TCRM for Correction of Cheek Including Fine Lines · NA · active not recruiting
NCT05986630 — Safety and Effectiveness Evaluation of TEOSYAL® TPVM Versus COMPARATOR for the Remodeling of the Lower Face · NA · active not recruiting
NCT05133739 — RHA®4 for Midface Volume Deficiency · completed
NCT05349799 — TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02195427 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Teoxane SA
Last refreshed: 26 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02195427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing